OXIS International Names New CEO

The board of directors of OXIS International Inc. (Portland, OR) has appointed Paul C. Sharpe CEO of the company, effective immediately. He was also appointed to the OXIS board.

Before joining OXIS, Sharpe served vice president of neurosciences project management at SmithKline Beecham. Previously, he held posts at Roche and the Medicine Control Agency, Britain's equivalent to the Food and Drug Administration.

Sharpe's appointment comes at a time when OXIS is undertaking a restructuring under which it will become entirely focused on the development of pharmaceutical products and will divest its non-therapeutic assets. Sharpe will assume the CEO position from Rogers who will focus his efforts on the divestiture program.

OXIS International is a drug development company dedicated to technologies to treat and prevent diseases associated with damage from free radicals and reactive oxygen species—diseases of oxidative stress.

For more information: Ray R. Rogers, Chairman, OXIS International Inc., 6040 N. Cutter Circle, Ste. 317, Portland , OR 97217. Tel: 503-283-3911. Fax: 503-283-4058.

Edited by Jim Pomager